10-K · March 31, 2026
Lixte Biotechnology Holdings, Inc. reported a significant net loss of $6.01 million for the year ended December 31, 2025, primarily driven by increased operating expenses, particularly in general and administrative…
Earnings analysis · 10-Q
NMAD earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text does not include income statement, balance sheet, cash flow, or segment results, so revenue, margins, EPS, liquidity, and cash-burn trends cannot be assessed. Management reported effective…
Read full summary
The extracted 10-Q text does not include income statement, balance sheet, cash flow, or segment results, so revenue, margins, EPS, liquidity, and cash-burn trends cannot be assessed. Management reported effective disclosure controls as of June 30, 2026 and no material changes to the risk factors disclosed in the December 31, 2025 Form 10-K. The merger agreement dated June 11, 2026 and amended June 30, 2026 is the principal corporate development disclosed in the provided text.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure Controls Deemed Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance that required information was reported on time.
-
Merger Transaction Progresses
The company filed a merger agreement dated June 11, 2026, involving Lixte Biotechnology Holdings, NBD Merger Sub, and NOMAD Transportable Power Systems; Amendment No. 1 was dated June 30, 2026.
-
No Insider Trading Plans Changed
No director or officer adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the six months ended June 30, 2026.
What to watch
-
Legacy 2025 Risks Remain Material
The company states that the risk factors in its 2025 Form 10-K, covering the fiscal year ended December 31, 2025, could materially adversely affect its business, financial condition, results, and cash flows. No material changes to those risks were identified as of the August 14, 2026 filing date.
-
Merger Execution Uncertainty
The merger agreement dated June 11, 2026 was amended on June 30, 2026, indicating that the transaction remains subject to amendment-related execution and closing uncertainty.
Management's outlook
No quantitative revenue or EPS outlook is provided in the extracted 10-Q text; outlook appears deferred to an earnings release or call.
Earlier filings 3
10-Q · November 12, 2025
Lixte Biotechnology Holdings, Inc. reported a net loss of $3.47 million for the nine months ending September 30, 2025, widening from a loss of $2.97 million in the prior year. The company continues to show no revenue…
10-Q · August 7, 2025
Lixte Biotechnology Holdings, Inc. reported no revenues for the second quarter of 2025, maintaining consistent operational losses amidst ongoing drug development efforts. Notable reductions in operating expenses were…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.